The stock went from a closing price of $26.52 on Feb. 27, the day the Pasadena-based pharmaceutical manufacturer reported earnings after the market closed, to $22.79 the following day, a decrease of ...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease ...

GENEVA--(BUSINESS WIRE)--Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, today announced that it has signed four commercial license ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bispecific antibodies are drugs designed to hit two targets at the same time. The Xencor drug, plamotamab, targets CD20, an antigen on B-cell tumors, and CD3, a receptor on T cells that plays a role ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Xencor demonstrates strong YoY revenue growth through achieved milestones with major industry partners. The strategic sale of royalty interests strengthens Xencor's balance sheet and provides ...

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and ...

-- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion ...